Cabergamoun 2 Tablets

Cabergamoun 2 Tablets

Description:

Cabergamoun 2 Tablets is a prescription dopamine agonist medicine containing cabergoline, an ergot-derived long-acting prolactin inhibitor. It is primarily used to treat hyperprolactinemic disorders (elevated prolactin levels), such as those caused by prolactin-secreting pituitary adenomas (prolactinomas) or idiopathic hyperprolactinemia. By selectively stimulating dopamine d2 receptors, Cabergamoun effectively reduces prolactin secretion, helping restore normal hormonal balance, menstrual regularity, fertility, and sexual function. It may also be used as part of the management of Parkinsonian syndrome, either as monotherapy in early disease or as an adjunct to levodopa in advanced stages, under specialist supervision.

Indications:

• Treatment of hyperprolactinemic disorders, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas).
• Management of symptoms related to elevated prolactin levels such as menstrual irregularities (amenorrhea, oligomenorrhea), galactorrhea, infertility, and decreased libido associated with hyperprolactinemia.
• Adjunctive treatment in certain patients with Parkinsonian syndrome, as monotherapy during initial symptomatic management or in combination with levodopa in advanced disease (as directed by a neurologist).
• Reduction of prolactin levels to help normalize gonadal function in both men and women with hyperprolactinemia.

Active Ingredients / Key Components:

• Cabergoline – 0.5 mg per tablet (dopamine d2 receptor agonist, prolactin inhibitor)
• Excipients: Exact inactive ingredients (lactose, binders, coloring agents, etc.) are not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.).

Dosage & Administration / How to Use:

• Cabergamoun is a prescription-only medicine and must be used exactly as directed by your physician.
• For hyperprolactinemia (typical adult regimen – for reference only, your doctor may adjust): A common starting dose is 0.5 mg per week, usually given as 0.25 mg twice weekly. The dose may be gradually increased based on prolactin levels and clinical response, up to a maximum weekly dose determined by the treating physician.
• For Parkinsonian syndrome: Dosing is individualized and usually starts at a low dose, then titrated upward under specialist supervision. Follow your neurologist’s instructions strictly.
• Tablets are usually taken with food to improve gastrointestinal tolerability and reduce nausea.
• Swallow the tablet whole with a sufficient amount of water; do not crush or chew unless your doctor advises otherwise.
• Take the medicine on the same days each week to help you remember your schedule (e.g., Monday and Thursday).
• If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose. Do not double the dose to make up for a missed dose. Consult your doctor if multiple doses are missed.
• Duration of treatment depends on your condition, prolactin levels, and medical evaluation. Do not stop treatment abruptly without consulting your doctor, as symptoms may return.

Clinical Benefits:

• Effectively lowers elevated prolactin levels, helping to normalize endocrine function.
• Helps restore regular menstrual cycles and ovulation in women with hyperprolactinemia-related menstrual disturbances and infertility.
• Reduces symptoms such as galactorrhea (inappropriate breast milk production) and breast tenderness associated with high prolactin.
• Improves reproductive and sexual function in both men and women by correcting hyperprolactinemia-related hormonal imbalance.
• Provides long-acting dopamine d2 receptor stimulation, allowing for convenient once- or twice-weekly dosing compared with older dopamine agonists.
• When used in Parkinsonian syndrome, may help improve motor symptoms such as rigidity, bradykinesia, and tremor as part of a comprehensive treatment plan.

Warnings & Contraindications:

• Use only under medical supervision. Cabergamoun is a potent dopamine agonist and prolactin inhibitor and is not suitable for self-medication.
• Contraindications: Known hypersensitivity to cabergoline, other ergot derivatives, or any component of the formulation; history of pulmonary, pericardial, or retroperitoneal fibrotic disorders; evidence of cardiac valvulopathy on echocardiography; uncontrolled hypertension.
• Patients with a history of valvular heart disease, serious cardiovascular disorders, pulmonary disease, or fibrotic conditions must be carefully evaluated before starting treatment. Baseline and periodic echocardiography may be recommended.
• May cause symptomatic hypotension, especially at treatment initiation or when used with other antihypertensive medications. Caution is advised in patients with cardiovascular disease.
• May cause somnolence and sudden sleep onset episodes. Patients should avoid driving or operating machinery until they know how the medicine affects them.
• Use with caution in patients with severe hepatic impairment, psychiatric disorders (especially history of psychosis), or peptic ulcer disease.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Cabergoline is generally not recommended during pregnancy unless clearly needed and prescribed by a specialist. Breastfeeding is usually not advised while taking cabergoline because it suppresses lactation.
• Inform your doctor about all other medicines you are taking, especially other dopamine agonists, antipsychotics, antihypertensives, macrolide antibiotics, or any ergot derivatives, to avoid interactions.
• Not intended to diagnose, treat, cure, or prevent any disease without appropriate medical evaluation and prescription.
• Keep out of reach of children. Accidental ingestion can be dangerous.

Side Effects:

• Common side effects: Nausea, vomiting, abdominal discomfort, constipation, dizziness, headache, fatigue, weakness, and postural hypotension (drop in blood pressure when standing).
• Less common side effects: Palpitations, flushing, peripheral edema, nasal congestion, depression, anxiety, insomnia, or changes in libido.
• Serious side effects (seek immediate medical attention): Signs of cardiac valvulopathy (shortness of breath, swelling of legs, chest pain), severe or persistent abdominal or chest pain, persistent cough, difficulty breathing, sudden severe headache, visual disturbances, confusion, hallucinations, or signs of allergic reaction (rash, itching, swelling of face or throat, severe dizziness, difficulty breathing).
• If you experience troublesome or persistent side effects, contact your doctor promptly. Dose adjustment or discontinuation may be required.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the tablets in their original blister or container, tightly closed. Do not store above the temperature specified on the package (exact temperature not available in the current information). Keep out of reach of children.

Specifications:

• Active ingredient: cabergoline 0.5 mg per tablet.
• Form: oral tablet.
• Pack size: 2 tablets per pack.
• Intended use: prescription dopamine agonist for hyperprolactinemia and selected Parkinsonian patients, as directed by a physician.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.